Circulating T cell subsets are altered in individuals with chronic spinal cord injury by Monahan, R. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2015
Circulating T cell subsets are altered in individuals
with chronic spinal cord injury
R. Monahan
Northwell Health
A. Stein
Hofstra Northwell School of Medicine
K. Gibbs
Northwell Health
M. Bank
Hofstra Northwell School of Medicine
O. Bloom
Hofstra Northwell School of Medicine
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.
Recommended Citation
Monahan R, Stein A, Gibbs K, Bank M, Bloom O. Circulating T cell subsets are altered in individuals with chronic spinal cord injury. .
2015 Jan 01; 63(1-3):Article 1381 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/1381. Free full text
article.
NEUROIMMUNOLOGY
Circulating T cell subsets are altered in individuals
with chronic spinal cord injury
Rachel Monahan1 • Adam Stein2 • Katie Gibbs1,2 • Matthew Bank3 •
Ona Bloom1,2,3,4
Published online: 6 October 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Traumatic spinal cord injury (SCI) induces changes in the immune system, both acutely and chronically. To
better understand changes in the chronic phase of SCI, we performed a prospective, observational study in a research
institute and Department of Physical Medicine and Rehabilitation of an academic medical center to examine immune
system parameters, including peripheral immune cell populations, in individuals with chronic SCI as compared to unin-
jured individuals. Here, we describe the relative frequencies of T cell populations in individuals with chronic SCI as
compared to uninjured individuals. We show that the frequency of CD3? and CD3? CD4? T cells are decreased in
individuals with chronic SCI, although activated (HLA-DR?) CD4? T cells are elevated in chronic SCI. We also
examined regulatory T cells (Tregs), defined as CD3? CD4? CD25? CD127lo and CCR4?, HLA-DR? or CCR4? HLA-
DR?. To our knowledge, we provide the first evidence that CCR4?, HLA-DR? or CCR4? HLA-DR? Tregs are expanded
in individuals with SCI. These data support additional functional studies of T cells isolated from individuals with chronic
SCI, where alterations in T cell homeostasis may contribute to immune dysfunction, such as immunity against infections or
the persistence of chronic inflammation.
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Introduction
Traumatic spinal cord injury (SCI) affects approximately
276,000 Americans [1]. It is increasingly clear that many
individuals living with SCI have altered immune system
responses, which include hallmarks of inflammation,
immunosuppression and autoimmunity [2–5]. There is also
a growing appreciation of a critical balance needed
between distinct innate and adaptive immune cell subsets
in order to maintain normal immune function and that
various aspects of this balance may be disrupted after SCI
[4, 6, 7].
The mechanisms that contribute to immune dysfunction
in individuals with SCI are currently unclear and likely to
be multifactorial. Some aspects of immune dysfunction,
particularly the high susceptibility to infection, have been
partially attributed to neurogenic bowel and bladder
effects. However, both the stroke and SCI clinical and
research communities have noted the influence of interac-
tions between the autonomic nervous system, particularly
the sympathetic nervous system, and the immune system
after neurological injury [4, 5, 8, 9]. This concept is further
bolstered by recent studies of the inflammatory reflex,
which describe how the vagus nerve of the parasympathetic
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nervous system regulates immune system function [10, 11].
For example, normal T and B cell functions are regulated
by the presence of an intact vagus nerve [12, 13].
Studies in animal models demonstrated dysregulation of
T cell function after SCI. Intraspinal T cells are observed
later than 8 weeks post-SCI [6, 14]. In a rat model, CD3?
T lymphocytes were reduced by *30 % for the first
2 weeks following SCI [15]. Regulatory T cells (Tregs)
have been proposed to play distinct roles within the spinal
cord at different phases of recovery after SCI [16].
Depletion of CD4? CD25? Tregs improved neuronal sur-
vival after CNS injury in rats or mice, and their presence
worsened neuronal survival measured at 1–2 weeks post-
injury, with or without low-dose irradiation [17, 18]. The
number of infiltrating Tregs at the injury site peaked at
2 weeks post-SCI, coinciding with their expression of the
chemokine receptor CCR4 [16]. In the same study, Tregs
played a negative role in tissue remodeling acutely and a
positive role in the subacute and chronic phases of SCI,
demonstrating that the roles of T cell subsets may change
during phases of recovery after SCI [16].
A limited number of studies have documented altered
population frequencies in vivo or activities in vitro of
innate or adaptive immune cells isolated from individuals
with acute or chronic SCI. In the 1990s, Campagnolo et al.
[9, 19] showed that circulating lymphocytes isolated from
individuals with chronic complete cervical SCI had
impaired function as compared to uninjured controls; they
hypothesized that this may have been due to interruptions
of the sympathetic nervous system and discussed implica-
tions for infection rates in SCI. Another study of adaptive
immune cells from individuals with SCI demonstrated
dampened T cell function during the first 3 months post-
SCI and that improvements in immune cell function cor-
related with rehabilitation therapy [20]. A later study by
Campagnolo et al. [21] demonstrated a similar frequency of
total lymphocytes, but elevated percentage of CD3? and
CD3? CD4? T cells in individuals with chronic SCI.
Immune cell function is currently being investigated in the
European SCIentinel study of ‘‘neurogenic immune
depression,’’ with information collected within 2 and at
10 weeks after SCI, including clinical data and immune
phenotypes, such as HLA-DR levels on monocytes, lym-
phocyte subset distribution and function ex vivo, as well as
cytokines and gene expression profiling of peripheral
lymphocytes [22].
Here, we characterized T cells and regulatory T cells in
individuals with chronic SCI (C1 year from initial SCI) as
compared to uninjured individuals, using current molecular
definitions of T cell subsets. We find a diminished fre-
quency of total CD4? T cells in individuals with chronic
SCI, although more of them are activated. To our
knowledge, we also provide the first evidence of elevated
regulatory T cells in individuals with chronic SCI.
Methods
Study participants
The local institutional review board approved this study,
and informed consent was obtained from all participants
prior to study enrollment. Inclusion criteria for individuals
with SCI were: C18 years old, a history of SCI at any level,
an initial injury that occurred C1 year prior and injury
classification with an American Spinal Injury Association
Impairment Scale (AIS) grade of A–D. Potential SCI par-
ticipants were excluded or study visits rescheduled if they
had a concurrent infection as indicated by laboratory or
clinical evidence, pressure ulcers, cancer, chemotherapy,
neutropenia or autoimmune disease. Uninjured participants
were C18 years old, without history of SCI, and selected to
be within an age range similar to the chronic SCI partici-
pants. Peripheral blood samples were collected into sodium
heparin-coated tubes via standard venipuncture. Data are
derived from male individuals with SCI (N = 22 T cell,
N = 19 Treg) or uninjured controls (N = 11, T cells and
Treg; Table 1). Due to technical issues with sample pro-
cessing or staining, one participant included in the Treg
analysis was not included in the T cell analysis and four
participants included in the T cell analysis were not
included in the Treg analysis. Complete omission of these
participants (N = 5) does not eliminate the significance (P
values\0.05) of the findings in either the T cell or Treg
analysis. Additional peripheral immune cell types and
immune system data analyzed from these and other par-
ticipants recruited in this study will be described elsewhere.
Flow cytometry
Peripheral blood leukocytes were isolated from blood using
Ficoll Paque Plus Gradient (GE Healthcare), according to
manufacturer’s instructions. Cells (2 9 106 cells/100 ll)
were incubated for 25 min on ice in the dark with anti-
bodies conjugated to fluorophores, washed in FBS buffer
(BD Biosciences Cat# 554656) and fixed in 4 %
paraformaldehyde. Antibodies were purchased from BD
Biosciences (BD), unless otherwise indicated. T cell panel
contained the antibodies: CD3-Alexa 700 (Cat# 557943),
CD4-PerCP-Cy5.5 (Cat# 560650), CD8-APC-Cy7 (Cat#
557760), CD38-APC (Cat# 555462) and HLA-DR-FITC
(Miltenyi Cat# 130-095-295). (CD69 was also included in
the panel, but failed to stain sufficient numbers of cells and
so was not used for analysis.) The Treg panel contained the
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following antibodies: CD3-Alexa 700 (Cat# 557943), CD4-
PerCP-Cy5.5 (Cat# 560650), CD25-PE (Cat# 557138),
CD127-APC (Biolegend Cat# 351316), CCR4-PE-Cy7
(Biolegend Cat# 359410) and HLA-DR-FITC (Miltenyi
Cat# 130-095-295). (CD45RO was also included in the
panel, but was not used in the analysis.) At least 100,000
and at most 480,000 total events were collected using a BD
LSRII Flow Cytometer. Spectral compensation was per-
formed with compensation beads (BD) on each day of
staining. Analysis was performed using FlowJo software
(Treestar, Inc). Cells were first gated as leukocytes using
forward (FSC) versus side scatter (SSC), and then, the
singlet population was selected for T cell subset analyses.
Frequencies reported are of the parent populations.
Statistical analysis
The nonparametric Mann–Whitney test was used to analyze
differences between groups, with significance set at
P\ 0.05. The Kruskal–Wallis test was used to analyze dif-
ferences among chronic SCI participants, according to injury
Table 1 Clinical and demographic features of study participants
(A) Individual chronic SCI participants
# Age Mechanism Level AIS T cell TReg
A 69 Fall T1 A X X
B 28 Other T12 C X X
C 78 Sports C4 D X X
D 45 Sports C5 A X X
E 64 Fall T8 A X X
F 62 Fall C5 D X
G 64 Sports T2 A X X
H 56 MVA C6 D X X
I 57 MVA T5 A X X
J 58 Fall L2 D X X
K 80 MVA C8 A X X
L 40 MVA C4 B X X
M 34 Sports C3 C X X
N 63 Sports C4 A X
O 60 Sports C1 D X X
P 56 Fall T7 A X X
Q 55 Sports L5 D X
R 45 Other C7 A X X
S 55 MVA T11 B X X
T 52 Fall T11 A X
U 72 MVA T4 A X
V 59 Sports C6 A X X
W 40 Other T11 A X X
Individual uninjured participants
# Age T cell Treg
AA 55 X X
BB 53 X X
CC 66 X X
DD 52 X X
EE 53 X X
FF 51 X X
GG 61 X X
HH 53 X X
II 49 X X
JJ 31 X X
KK 28 X X
(B) Summary of demographics among T cell participants
Participants (n) Uninjured Chronic SCI P value
Age (mean, SEM) 50, 3 56, 3 0.14
Chronic SCI: n (%)
Mechanism of injury Injury level
MVA 6 (27.3) Cervical 10 (45.5)
Fall 5 (22.7) Thoracic 10 (45.5)
Sport 8 (36.4) Lumbar 2 (9.0)
Violence 3 (13.6)
Table 1 continued
(B) Summary of demographics among T cell participants
Participants (n) Uninjured Chronic SCI P value
AIS grade
A 13 (59.1) Years from
injury [mean
(SEM)]
18.1 (2.7)
B 2 (9.1)
C 2 (9.1)
D 5 (22.7)
(C) Summary of demographics among TReg cell participants
Participants (n) Uninjured Chronic SCI P value
Age (mean, SEM) 50, 3 56, 3 0.18
Chronic SCI: n (%)
Mechanism of injury Injury level
MVA 5 (26.3) Cervical 10 (52.6)
Fall 5 (26.3) Thoracic 8 (42.1)
Sport 6 (31.6) Lumbar 1 (5.3)
Violence 3 (15.8)
AIS grade
A 10 (52.6) Years from injury
[mean (SEM)]
15.2 (2.4)
B 2 (10.5)
C 2 (10.5)
D 5 (26.3)
This table provides clinical and demographic characteristics of study partici-
pants. (A) Individual participant characteristics are provided. An ‘‘X’’ indicates
if participant was included in analysis for T cells and/or TReg panel analysis.
(B) A summary of characteristics is provided for participants analyzed for each
panel
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levels and neurological injury status. All statistics were per-
formed using Prism GraphPad 5 Software for Mac OSX.
Results
Participant characteristics
We analyzed circulating T and regulatory T cells isolated
from chronic SCI (N = 22, 19, respectively) and uninjured
(N = 11) participants (Table 1). Clinical and demographic
features of participants are shown in Table 1. The age of
uninjured participants was 50 ± 3 (mean years ± SEM)
and ranged 28–66 years. The age of chronic SCI partici-
pants was 56 ± 3 (mean years ± SEM) and ranged 28–
80 years. Among chronic SCI participants, the most com-
mon mechanism of injury was sports (35 %); other
mechanisms included falls (26 %), motor vehicle accidents
(MVAs, 26 %) or violence other (13 %). Among SCI
participants, the time from initial injury ranged from 1 to
44 years; the average time from initial injury was 17 ± 2.7
(mean years ± SEM). The ASIA Impairment Scale (AIS)
grades among SCI participants were: A (56.5 %), B
(8.7 %), C (8.7 %) and D (26.1 %). The injury level most
common among SCI participants was cervical (48 %),
followed by thoracic (43 %).
T cell characterization
To better understand the potential roles of T cell subsets
in immune dysfunction in human chronic SCI, T cell
subsets were distinguished using cell surface markers
currently considered to be characteristic of human T cell
susbets [23]. PBMCs were isolated from blood and cell
subsets labeled with multiantibody cocktails, as described
in ‘‘Methods.’’ T lymphocyte subsets were characterized
by the expression of cell surface markers: all T cells
(CD3?), CD4? or CD8? T cells (CD3? CD4? or CD3?
CD8?), alone and in combination with HLA-DR
(MHCII), which is present on activated human T cells [23,
24] (Fig. 1).
Individuals with chronic SCI (N = 22) had a signifi-
cantly lower frequency of CD3 ? T cells, as compared to
uninjured individuals (N = 11; Fig. 2a, P\ 0.03). The
percentage of CD3? CD4? T cells was also significantly
lower in chronic SCI as compared to uninjured individuals
(Fig. 2b, P\ 0.04). However, the frequency of activated
CD4? T cells was elevated in individuals with SCI, as
indicated by HLA-DR expression (Fig. 2c, P\ 0.003),
and particularly in individuals with neurologically com-
plete injuries (N = 13; Fig. 2d, P\ 0.01) or in individ-
uals with injury levels at T5 and above (N = 14; Fig. 2e,
P\ 0.01). This is of interest because sympathetic nervous
system innervation of immune organs occurs at T6, as
described above [4, 5]. The mean fluorescence intensity of
HLA-DR on CD4? T cells was not significantly different
between SCI and uninjured individuals (P[ 0.57,
mean ± SEM 937 ± 98 vs. 862 ± 76, respectively).
These data indicate a disruption in homeostasis of the
CD4? T cell subset in individuals with chronic SCI.
The percentage of CD8? T cells did not differ signifi-
cantly between chronic SCI (N = 22) and uninjured indi-
viduals (N = 11; P\ 0.19, median ± SEM median
19 ± 2 vs. 23 ± 2 %, respectively). The mean fluores-
cence intensity of HLA-DR on CD8? T cells was not
significantly different between SCI and uninjured individ-
uals (P[ 0.8, mean ± SEM 929 ± 106 vs. 1063 ± 157,
respectively).
Regulatory T cells are a heterogeneous population of T
cells which can suppress activation of most other innate
and adaptive immune cell types and are dysregulated in
neurological and non-neurological chronic diseases,
including multiple sclerosis, type I diabetes and rheumatoid
arthritis [7, 25, 26]. Due to their importance in modulating
immune responses generally and reports of immune
depression in SCI [4, 5, 22, 27, 28], we also measured the
frequency of regulatory T cells (TRegs) here. While the
transcription factor FoxP3 is the most widely used marker
for murine CD4? TRegs, it requires intracellular staining
(which precludes functional assays) and its expression
patterns and stability in humans are less well understood
Fig. 1 Gating strategy of T cell subsets. Flow cytometry dot plots
illustrate the gating of all T cells, as indicated by the expression of
CD3 (a). CD3? cells were then gated for the expression of CD8? or
CD4? (b). The proportion of activated T cells, as indicated by HLA-
DR expression, was identified on CD4? (c) or (d) CD8? T cells
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[7]. CD4? TRegs express CD3? CD4? and high levels of
CD25, the IL-2 receptor. The chemokine receptor CCR4?,
which facilitates migration, was also shown to be present
on most human peripheral blood TRegs, where it correlates
with the expression of Foxp3? [23, 29, 30]. CD127, the
alpha chain of the IL-7 receptor, is inversely correlated
with FoxP3? in human TRegs [31, 32] and in combination
with CD25? high CD4? T cells, identifies TRegs in human
peripheral blood [33, 34]. Expression of HLA-DR on TRegs
is currently accepted to define a population of terminally
differentiated, effector TRegs with high suppressive activity
[25, 35]. This population is functionally defective in cells
isolated from individuals with multiple sclerosis [25].
Therefore, to characterize TRegs here, we used a gating
strategy that included the expression of CD3?, CD4?,
high expression of CD25, low or no expression of CD127,
and expression of CCR4, HLA-DR (MHCII) or both CCR4
and HLA-DR (Fig. 3).
Using the TRegs antibody panel, we again observed a
lower percentage of CD3? T cells (P\ 0.03, Fig. 4a) and
a trend toward a lower percentage of CD4? T cells in
individuals with chronic SCI (N = 19) as compared to
uninjured individuals (N = 11; P\ 0.07, Fig. 4b). The
percentage of CD3? CD4? T cells that were CD25?
CD127lo was not significantly different between chronic
SCI and uninjured individuals (P\ 0.15, Fig. 4c). How-
ever, we observed a significant increase in the proportion of
CD25? CD127lo CD4? T cells that expressed CCR4?
(P\ 0.0002, Fig. 4d). Among individuals with SCI, this
difference was significant in individuals with neurologi-
cally incomplete (N = 9) or complete injuries (N = 10)
(P\ 0.01, P\ 0.05, respectively) and in individuals with
injuries at level T5 and above (N = 13) or T6 and below
(N = 6; P\ 0.01 and P\ 0.05, respectively). We also
observed a significant increase in the proportion of CD25?
CD127lo CD4? T cells that expressed HLA-DR
Fig. 2 Frequency of major T
cell subsets is altered in
individuals with chronic SCI.
Frequency of CD3? (a) or
CD4? cells within the CD3?
population (b) is lower in
individuals with chronic SCI as
compared to a control group.
The percentage of CD4? cells
that are activated is elevated in
chronic SCI, as indicated by the
expression of HLA-DR (c),
particularly in those with
neurologically complete (AIS
grade A) injuries (d) or injuries
at neurological level T5 and
above (e). Significant P values
are shown
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(P\ 0.02, Fig. 4e) or both CCR4? and HLA-DR?
(P\ 0.003, Fig. 4f).
Discussion
Here, we find disruptions in the frequencies and activation
status of different subsets of peripheral T cells in indi-
viduals with chronic SCI. Specifically, we find decreased
frequencies of CD3? and CD4? T cells, particularly in
individuals with complete or high level SCI (Figs. 2a, b,
4a, b). However, the frequency of activated CD4? T
cells was elevated in individuals with SCI (Fig. 2c–e).
We also find elevated frequencies of CD4? Tregs in
individuals with chronic SCI, particularly in CD25?
CD127loCCR4? (Fig. 4d), CD25? CD127loHLA-DR?
(Fig. 4e) and CD25? CD127loCCR4? HLA-DR?
(Fig. 4f) populations.
T cells are critical for proper function of the adaptive
immune system and have been studied in the context of
responses to infection in SCI models. After mouse hepatitis
virus infection 1 week post-injury, SCI mice had increased
mortality compared to infected mice without SCI, which
was accompanied by reduced IFNy? CD4? T cells, virus-
specific T cells and total CD4? T cells, in addition to
increased viral replication [36]. In another study of chronic
SCI in mice, CD4? and CD8? T cell function were also
decreased, as indicated by diminished cytokine production
ex vivo and higher expression of an exhaustion markers
[37]. Interestingly, the same study showed that CD8? dys-
function was promoted by impairment of the sympathetic
nervous system and could be modulated by norepinephrine
[37].
Much less is known about T cell biology in human
SCI, but there is evidence of altered T cell biology.
CD4? T cell frequency and function are diminished in
individuals with acute SCI [8, 28]. There is also evidence
of altered CD4? T cell biology in later phases of
recovery after SCI. A study of SCI cadavers showed that
elevated numbers of intraspinal CD4? and CD8? T
cells were present weeks after SCI [38]. T cells isolated
from bone marrow of individuals with chronic SCI had
impaired activity in vitro [39]. Serum IL-2R (CD25)
levels and lymphocyte proliferation decreased in indi-
viduals within the first 3 months post-SCI and then
increased to normal or near-normal levels at year post-
injury [8, 20, 40]. Infections were recently identified as
an independent risk factor for poor neurological recovery
for the first year after SCI and are also a risk factor for
poor neurological recovery in stroke [8, 27, 41, 42].
Taken together, the present findings of altered T cell
subsets in individuals chronic SCI may be relevant to
infection susceptibility among this population as well
as to other manifestations of immunosuppression or
immune system dysfunction observed in chronic SCI [4,
5]. Additional studies are necessary to evaluate the rel-
evance of these findings to the general SCI population
and to investigate whether functional activities of
altered T cell subsets, such as helper and suppressor
activities, are also altered in cells isolated from indi-
viduals with SCI.
Study limitations include a relatively small cohort size
and unequal gender distribution, so only data from male
participants are described. Among SCI participants, the
time from initial injury varied greatly, we did not recruit
an equal number of individuals with neurologically
complete or incomplete injuries, nor did we recruit an
equal number of individuals with high or low injury
levels. Also, we did not collect information on acute SCI
in the same individuals, nor did we collect information on
participants’ rehabilitation programs or general activity
levels, which may potentially influence immune responses
[20, 40].
Fig. 3 Gating strategy of regulatory CD4? T Regs. Flow cytometry
dot plots illustrate the gating of TRegs. Cells expressed CD3 (a) and
CD4 (b). CD4? T cells were then gated for the expression of CD25
and low expression of CD127 (c). CD25? CD127lo T cells were then
gated for the expression of CCR4 (d) and HLA-DR (e)
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